Edition:
United Kingdom

GlaxoSmithKline Consumer Healthcare Ltd (GLSM.NS)

GLSM.NS on National Stock Exchange of India

6,887.95INR
5:49am GMT
Change (% chg)

Rs-43.05 (-0.62%)
Prev Close
Rs6,931.00
Open
Rs6,900.05
Day's High
Rs6,940.00
Day's Low
Rs6,882.00
Volume
5,591
Avg. Vol
34,061
52-wk High
Rs7,948.00
52-wk Low
Rs5,725.00

Latest Key Developments (Source: Significant Developments)

India's Glaxosmithkline Consumer Healthcare Dec Qtr Profit Rises
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - GlaxoSmithKline Consumer Healthcare Ltd ::DEC QUARTER PROFIT 2.21 BILLION RUPEES VERSUS PROFIT OF 1.64 BILLION RUPEES LAST YEAR.DEC QUARTER REVENUE FROM OPERATIONS 11.17 BILLION RUPEES VERSUS 10.39 BILLION RUPEES LAST YEAR.  Full Article

Hindustan Unilever Exec Says Expect Deal With GSK Consumer To Be EPS Accretive For Co
Monday, 3 Dec 2018 

Dec 3 (Reuters) - Hindustan Unilever Ltd CFO Srinivas Phatak::EXEC SAYS EXPECT TO GROW PORTFOLIO IN DOUBLE DIGITS IN MEDIUM TERM, POST DEAL - CONF CALL.EXEC SAYS EXPECT DEAL TO BE EPS ACCRETIVE FOR CO - CONF CALL.  Full Article

India's Glaxosmithkline Consumer Healthcare Approves Amalgamation With Hindustan Unilever
Monday, 3 Dec 2018 

Dec 3 (Reuters) - Glaxosmithkline Consumer Healthcare Ltd ::SAYS APPROVED A SCHEME OF AMALGAMATION BETWEEN COMPANY AND HINDUSTAN UNILEVER LIMITED.SHARE EXCHANGE RATIO FOR AMALGAMATION TO BE 4.39 EQUITY SHARES OF HUL FOR EVERY SHARE OF CO.SCHEME IS SUBJECT TO NECESSARY STATUTORY AND REGULATORY APPROVALS.  Full Article

GSK Says Considering Potential Deal Including Merger Of Its Consumer Healthcare Unit
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - GlaxoSmithKline Plc ::UPDATE ON REVIEW OF HORLICKS.GSK CONFIRMS THAT CONSIDERATION IS BEING GIVEN TO A POTENTIAL TRANSACTION THAT INCLUDES A MERGER OF GSKCH.MAJORITY OF HORLICKS AND OTHER GSK NUTRITION PRODUCTS SALES ARE GENERATED IN INDIA BY GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED.  Full Article

Hindustan Unilever Says Co Bound By Confidentiality Obligations Currently, In Reference To Deal For Horlicks
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - Hindustan Unilever Ltd ::SAYS CO BOUND BY CONFIDENTIALITY OBLIGATIONS CURRENTLY, IN REFERENCE TO DEAL FOR HORLICKS.  Full Article

GSK To Review Of Horlicks, Consumer Nutrition Products To Fund Novartis Deal
Tuesday, 27 Mar 2018 

March 27 (Reuters) - Glaxosmithkline Plc ::GLAXOSMITHKLINE - TRANSACTION WITH NOVARTIS EXPECTED TO BE ACCRETIVE TO ADJUSTED EARNINGS IN 2018 AND THEREAFTER, AND TO STRENGTHEN CASH FLOW GENERATION.GSK ALSO TO INITIATE STRATEGIC REVIEW OF HORLICKS AND OTHER CONSUMER NUTRITION PRODUCTS TO SUPPORT TRANSACTION FUNDING..‍REVIEW WILL INCLUDE AN ASSESSMENT OF GROUP'S SHAREHOLDING IN INDIAN SUBSIDIARY, GLAXOSMITHKLINE CONSUMER HEALTHCARE LTD​.STRATEGIC REVIEW WILL INCLUDE AN ASSESSMENT OF GSK'S 72.5% SHAREHOLDING IN COMPANY.‍EXPECTS OUTCOME OF STRATEGIC REVIEW TO BE CONCLUDED AROUND END OF 2018​.GLAXOSMITHKLINE - CONSUMER HEALTHCARE BUSINESS TO CONTINUE TO INVEST IN GROWTH OPPORTUNITIES FOR OTC, ORAL HEALTH BRANDS, SUCH AS SENSODYNE AND ENO.GLAXOSMITHKLINE - ACTIVELY INVESTING IN PHARMACEUTICAL, VACCINES BUSINESSES, INCLUDING BUILDING NEW MANUFACTURING CAPACITY IN VEMGAL, KARNATAKA, NASHIK.GLAXOSMITHKLINE - BUYOUT TO BE STRUCTURED AS CANCELLATION OF NOVARTIS' SHARES IN JV IN CONSIDERATION OF JOINT VENTURE PAYING BUYOUT PRICE TO NOVARTIS.GSK HAS ENTERED INTO A COMMITTED FACILITIES AGREEMENT TO SUPPORT FUNDING OF BUYOUT.AGREED TO PAY BREAK FEE OF $200 MILLION IN NOVARTIS DEAL.JOINT VENTURE WILL CONTINUE TO PAY DIVIDENDS TO GSK AND NOVARTIS IN ACCORDANCE WITH ITS ESTABLISHED PRACTICE UNTIL COMPLETION.  Full Article

India's Glaxosmithkline Consumer Healthcare Sept qtr profit up about 4 pct
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Glaxosmithkline Consumer Healthcare Ltd :Sept quarter net profit 1.92 billion rupees versus profit of 1.84 billion rupees last year.Sept quarter revenue from operations 11.15 billion rupees versus 11.93 billion rupees last year.  Full Article

Photo

Unilever swallows GSK's Indian Horlicks business for $3.8 billion

LONDON Unilever is to buy GlaxoSmithKline's Horlicks nutrition business for $3.8 billion (2.98 billion pounds), boosting the Anglo-Dutch group's position in India by adding the popular malted drink.